SGLT2 inhibitors decrease the risk of hospitalization and death for heart failure patients and improve cardiovascular outcomes regardless of type 2 diabetes status.

“subsequently there's been oh a good seven mega trials now you know between three and seventeen thousand patients in each study randomized to sglt2 inhibitor or placebo that shows that in fact these are the most potent drugs for i'm not for lowering sugar they do that modestly but for for improving cardiovascular prognosis reducing heart failure and renal failure and it's just amazing thing and subsequently there's been oh a good seven mega trials now you know between three and seventeen thousand patients in each study randomized to sglt2 inhibitor or placebo that shows that in fact these are the most potent drugs for i'm not for lowering sugar they do that modestly but for for improving cardiovascular prognosis reducing heart failure and renal failure and it's just amazing thing”